X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Sirio Europe invest in advanced manufacturing and green technologies at Brandenburg site

Content Team by Content Team
21st October 2020
in Manufacturing, News
Sirio Europe invest in advanced manufacturing and green technologies at Brandenburg site

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Sirio Europe – the leading European nutraceutical and pharmaceutical contract development and manufacturing organisation (CDMO), part of the Sirio group – announces the completion of a major overhaul of its Brandenburg site with advanced manufacturing and green technologies. The company has installed new HVAC systems, individual drying chambers, vegetarian softgel manufacturing equipment and a block heat & power plant. The improvements were implemented as part of Sirio Europe’s continuous efforts to further improve the quality and sustainability of manufacturing.

“One of the reasons behind the investments was that we wanted to be at the forefront of implementing greener solutions and energy-efficient manufacturing for our pharma customers. So while implementing new equipment, we also explored how we can improve the plant’s sustainability.” commented Dominique Baum, Managing Director at Sirio Europe

The HVAC systems increase the plant’s manufacturing capacity while further reducing the risk of product contamination. Similarly, by using only individual drying chambers, the company can control the temperature of individual products, which is more energy-efficient and improves the softgel drying process. Additionally, a new vegetarian softgel manufacturing line has been installed – transferring technology from Sirio’s Guangzhou plant – in response to the growing demand for plant-based nutraceuticals.

But in line with the company commitment to increased sustainability, the site upgrades will be supported by an energy-efficient block heat & power station, which is estimated to increase power output by up to 50% through combined heat and power (CHP). The technology captures and recycles heat – otherwise lost as waste – into thermal energy to power the new manufacturing equipment.

Baum added: “Installing the heat block & power station is a huge business benefit in terms of reducing energy consumption. For example, softgel production uses a lot of energy as strict parameters need to be adhered to – through CHP we can now manufacture softgels at a lower cost. But installing the heat block was also the right thing to do in terms of looking at ways to make manufacturing as sustainable as possible”.

The new plant upgrades form just a small part of wider drive at the Sirio Group to implement the most sustainable manufacturing processes of any nutraceutical CDMO globally. For example, the company exclusively sources ingredients from certified, sustainable suppliers, and are members of a number of certified sustainability groups, including the Friends of the Sea (part of the World Sustainability Organisation) and Marine Stewardship Council.

About the Ayanda plant

Ayanda belongs to Sirio Europe, the European based member of Sirio Group with more than 20 years of experience in contract manufacturing of nutraceutical and pharmaceutical private label softgel products, that not only comply with but exceed industry standards and expectations.

Ayanda’s core business is development and manufacturing of complex softgels containing up to 10 or more ingredients. The company has a strict focus on quality and is dedicated to exceeding global quality requirements.

Ayanda is a Pharma GMP approved site, holds IFS Food Standard and BRC certifications, both graded at highest score. Since sustainability matters more and more to customers and consumers, Ayanda is organic certified and holds two certificates for sustainable seafood: FOS (Friend of the Sea) and MSC (Marine Stewardship Council).

About SIRIO

Founded in 1993, Sirio Pharma Co., Ltd (SIRIO) is the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgel, capsule, tablet, powder, gummy, oral liquid, probiotics and other dosage forms. The company has extensive capabilities with multiple manufacturing sites in China, as well as manufacturing facilities in Europe and marketing teams in the USA. SIRIO is devoted to offering one-stop solutions including product developing, manufacturing, packaging and logistics to its customers.

SIRIO is approved by TGA-GMP, NPA/UL GMP, BRC, UL’s Management System 21 CFR Part 111, ISO 9001:2015 certification, and etc. Cooperating with many well-known nutraceutical companies, SIRIO is committed to providing products and service to customers all around the world.

Previous Post

ATMPS advanced therapy blockchain platform has successful testing with NHS partners

Next Post

New Functionality Added to Thermo Scientific SampleManager LIMS software for Manufacturing QA/QC and Contract Laboratories

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Thermo Scientific SampleManager LIMS software

New Functionality Added to Thermo Scientific SampleManager LIMS software for Manufacturing QA/QC and Contract Laboratories

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In